COMMD1 has a wide tissue expression pattern, is located in the cytosol and nucleus, and colocalizes with early and late endosomal markers (2) (3) (4) , maybe through interaction with phosphatidylinositol 4,5-bisphosphate (2) . COMMD1 has no known enzymatic function and is hypothesized to be an adaptor or scaffold protein.
Initially, COMMD1 was reported to regulate copper transport after dogs suffering from liver copper toxicosis were found to have COMMD1 loss of function mutations (11) . Although COMMD1 genetic variations are not linked to human copper overload disorders, COMMD1 does interact with the ATP7A and ATP7B copper transporters, which contain mutations in human copper deficiency or overload diseases (8) . COMMD1 was identified through a yeast two-hybrid screen to interact with the ␦-subunit of the epithelial sodium channel (ENaC) and subsequently three other ENaC subunits (␣␤␥) (1, 5) . Although the in vivo function of ␦ENaC is unknown, the ␣␤␥ENaC channel forms an aldosterone-induced, amiloridesensitive apically located Na ϩ absorption pathway in distal epithelia. Specific mutations in ENaC genes cause hypo-or hypertension through alteration of distal nephron Na ϩ absorption. The cystic fibrosis transmembrane conductance regulator (CFTR) is also located in epithelia and forms an apically located Cl Ϫ and HCO 3 Ϫ secretion pathway, which is attenuated when CFTR contains mutations causing cystic fibrosis leading to multiple symptoms including respiratory dysfunction. In the lung, Na ϩ absorption and Cl Ϫ secretion pathways may be coregulated; therefore it was interesting that COMMD1 was also found to interact with CFTR via a two-hybrid screen (4) . COMMD1 has a wider role in cellular physiology as it interacts with NF-B and HIF-1␣ transcription factors, HSP70, and proteins in the DNA damage response network (6, 10) . What is the link between COMMD1 and this diverse range of proteins? At present, COMMD1's ability to alter protein stability is the best candidate for a universal COMMD1 function. Extensive study in the NF-B pathway showed that COMMD1 promotes ubiquitination of NF-B subunits, thus targeting NF-B for degradation and decreasing NF-B-mediated tran- ENaC and CFTR are located at the apical membrane, and NKCC1 at the basolateral membrane. ATP7A and ATP7B localize to the trans-Golgi network, and in high intracellular copper concentrations, ATP7B traffics to subapical vesicles near the bile canalicular membrane in hepatocytes, and ATP7A is trafficked to the basolateral membrane in intestinal epithelia to facilitate copper exit from the cell. These proteins would not necessarily be located in the same cell type in vivo. COMMD1 variably regulates these transport proteins. scription (6) . A huge repertoire of single subunit or modular ubiquitin ligase enzymes is responsible for targeting ubiquitination of specific protein substrates. COMMD1 is known to promote the ubiquitin-conjugating ability of ubiquitin ligase complexes formed with a cullin protein backbone bound to a variety of adaptors and substrate binding proteins (7) . Does COMMD1 promote ubiquitination of ion transport proteins, and does this subsequently alter their location or function? The answer is not straightforward. COMMD1 increases ubiquitination of ENaC subunits, decreases ENaC cell surface population, and decreases amiloride-sensitive current (3, 5) . Knockdown of COMMD1 decreases the NKCC1-ubiquitin population, but paradoxically it appears to reduce the basolateral NKCC1 population (9) . Conversely, COMMD1 decreases ubiquitination of CFTR and increases CFTR cell surface population; however, COMMD1-mediated alterations in CFTR transport properties have not been reported. COMMD1 decreases the stability of both ATP7A and ATP7B, although this effect is expression system dependent (8) . Variability of the COMMD1 effects on ion transport proteins may be due to COMMD1 targeting regulatory proteins, or, COMMD1 may have flexible effects on different ubiquitin ligases. COMMD1 may have multiple domainspecific effects as it is the NH 2 -terminal domain of COMMD1 that interacts with NKCC1 (9), while it is the COOH-terminal COMM domain that interacts with ␦ENaC, ATP7A, CFTR, COMMD2-10, HIF1␣, and NF-B.
Ubiquitination is linked to protein trafficking pathways, and this link is underexplored for COMMD1 and ion transporters. COMMD1 binds more avidly to unstable mutant copper transporters which could potentially target these for degradation (8) , but COMMD1 does not appear to facilitate copper-induced movement of ATP7A/B from the trans-Golgi to the cell periphery. At the cell surface, COMMD1 may promote ENaC endocytosis through increasing ENaC ubiquitination (3), or have the opposite effect on CFTR (4). For NKCC1 there appears to be a trend for COMMD1 to stabilize NKCC1 at the basolateral membrane and to also play a role in NKCC1 recycling (9) .
What roles are played by COMMD2-10? Their in vivo functions are mostly unknown; however, COMMD proteins dimerize via their conserved COMM domains therefore homoand heterodimers likely occur in vivo (6) . Functional redundancy may disguise experimental observations focused on COMMD1, although COMMD1 Ϫ/Ϫ mice are embryonic lethal, suggesting that unique functions exist for COMMD proteins (10) .
To advance our understanding of COMMD1 effects on ion transporters, future studies should include 1) identifying other ion channels and transporters that interact with COMMD1 with the aim of identifying conserved COMMD1 binding motifs, 2) determining the mechanisms by which COMMD1 increases ubiquitination of some proteins and decreases that of others, 3) identifying the COMMD1-regulated ubiquitin ligases that target ion transport substrates, and finally, 4) ascertaining the types(s) of ubiquitin chains linked to ion transport proteins. In conclusion, COMMD1 has an intriguing but underexplored connection to ion transport proteins that are crucial for homeostasis and implicated in a variety of pathophysiological conditions.
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